Table 3 OAVs with E1A 13S, E1B19K or E1B55K deletion

Bladder cancer

XVir-N-31

Ad5-Delo3-RGD

∆E1A13S, ∆E1B19K

Intratumoral

Preclinical

[82]

Ultrasound guidance

Bladder cancer

Murine ewing sarcoma

Intratumoral

Preclinical

[83]

CDK4/6 inhibitor

Glioma

Intratumoral

Preclinical

[81]

Temozolomide

Glioblastoma

XVir-N-31-anti-PD-L1

Ad5-Delo3-RGD-PD-L1

∆E1A13S, ∆E1B19K, PD-L1 anbibody

Intratumoral

Preclinical

[85]

Nivolumab

Malignant ascites

Oncorine (H101)

∆E1B55K, partial E3 deletion

Intraperitoneal

Phase II

NCT04771676

[88]

Bladder cancer

Intravesical

Phase II

NCT05564897

Camrelizumab

Liver cancer

Transarterial

Phase III

NCT03780049

[89]

Chemoembolization

Liver cancer

Transarterial

Phase I

NCT05675462

Tislelizumab, lenvatinib

Colorectal cancer

Intratumoral

Preclinical

[90]

Anti-PD-1 monotherapy

Colorectal cancer

ONYX-015 (dl520)

Ad2/Ad5, ∆E1B55K

Intravenous

Preclinical

[91]

5-FU/leucovorin

Garcinoma metastatic to liver

Intraarterial

Phase II

[92]

Cervical cancer

Intratumoral

Preclinical

ChiCTR-OPC-15006142

[13]

Chemoradiotherapy

Carcinoma metastatic to lung

Intravenous

Preclinical

[93]

Head and neck cancer

Intratumoral

Phase II

NCT00006106

[94]

Cisplatin, fluorouracil

Melanoma

ZD55-IL-24

Ad2/Ad5, ∆E1B55K, IL-24

Intratumoral

Preclinical

[95]

Liver cancer

Intravenous

Preclinical

[14]

PEG/lipids/calcium phosphate

Renal cell carcinoma

Ad5-ZD55-CCL5-IL-12

∆E1B55K, CCL5, IL-12

Intratumoral

Preclinical

[22]

CA9-CAR-T

Colorectal cancer

ZD55-CD/5-FU

∆E1B55K, CD/5-FC

Intratumoral

Preclinical

[96]

Pancreatic cancer

Ad5-yCD/mutTKSR39rep-IL-12

∆E1B55K, HSV-TK. yCD and IL-12

Intratumoral

Phase I

NCT03281382

[97]

5-FC, gemcitabine/paclitaxel

Glioma

BioTTT001

Ad5-TD-nsIL-12

E1∆24, ∆E1B19K, and ∆E3gp19K, IL-12

Intratumoral

Phase I

NCT05717699

NCT05717712

Pancreatic cancer

Intraperitoneal

Preclinical

[98]

Colorectal cancer

OAV-CXCL10

∆E1B, CXCL10

Intratumoral

Preclinical

[99]

Anti-PD-1 monotherapy